461 related articles for article (PubMed ID: 21052701)
1. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
3. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain.
Kitawaki J; Kusuki I; Yamanaka K; Suganuma I
Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):212-6. PubMed ID: 21474232
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
[TBL] [Abstract][Full Text] [Related]
6. Effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Cramer SF
Arch Pathol Lab Med; 1998 Dec; 122(12):1045-6. PubMed ID: 9870847
[No Abstract] [Full Text] [Related]
7. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
8. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
10. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Nakashima M; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Nov; 25(11):2878-90. PubMed ID: 20829343
[TBL] [Abstract][Full Text] [Related]
11. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
12. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
13. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
Mizutani T; Sugihara A; Nakamuro K; Terada N
J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
15. Single or repeated gonadotropin-releasing hormone agonist treatment avoids hysterectomy in premenopausal women with large symptomatic fibroids with no effects on sexual function.
Perrone AM; Pozzati F; Di Marcoberardino B; Rossi M; Procaccini M; Pellegrini A; Santini D; De Iaco P
J Obstet Gynaecol Res; 2014 Jan; 40(1):117-24. PubMed ID: 24033631
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dienogest in thinning the endometrium before hysteroscopic surgery.
Kodama M; Onoue M; Otsuka H; Yada-Hashimoto N; Saeki N; Kodama T; Wakasa T; Funato T
J Minim Invasive Gynecol; 2013; 20(6):790-5. PubMed ID: 23830718
[TBL] [Abstract][Full Text] [Related]
17. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist use before hysterectomy.
Stovall TG; Summit RL; Washburn SA; Ling FW
Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
[TBL] [Abstract][Full Text] [Related]
19. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
20. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis.
Takaesu Y; Nishi H; Kojima J; Sasaki T; Nagamitsu Y; Kato R; Isaka K
J Obstet Gynaecol Res; 2016 Sep; 42(9):1152-8. PubMed ID: 27225336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
